RE: Invest analysts3 Feb 2025 11:33
ice
excellent post re the preclinical deals.
whilst we can all agree on the many shortcomings of the aim and the value it attributes to #avct , i’m of the opinion that our sp languishes at sub £1 as a direct consequence of our poor public relations strategy.
i can’t quite square the circle ! are they so **** sure that they are sat on a “gusher “ they don’t feel any need to “ spread the word “ or are they just not very at good at pr ?
last weeks deck being a case in point- i wonder what would the sp might have done had our cso michelle morrow (i though she came across quite well - not cc and not an r& d spotlight ) presented the data with a follow up from simon bennett on the number$ ?
after all , to use another oil metaphor you wouldn’t announce you were drilling for oil without mentioning how many barrell$ were in the ground !